NCT03410927: A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities

NCT03410927
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: HER2, HER3
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1|Phase 2
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: If HER2-negative, must have HER2 or HER3 molecular/genetic alteration
Exclusions: 
https://ClinicalTrials.gov/show/NCT03410927

Comments are closed.

Up ↑